100
Views
12
CrossRef citations to date
0
Altmetric
Editorial

Phosphorylated α-synuclein as a potential biomarker for Parkinson’s disease and related disorders

, &
Pages 115-117 | Published online: 09 Jan 2014

References

  • Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science296, 1991–1995 (2002).
  • Ferreira ST, Klein WL. The toxic oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease. Neurobiol. Learn. Mem.96, 529–543 (2011).
  • Spillantini MG, Crowther RA, Jakes R et al. α-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA95, 6469–6473 (1998).
  • El-Agnaf OMA, Salem SS, Paleologou KE et al. α-synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including human plasma. FASEB J.17, 1945–1947 (2003).
  • Tokuda T, Salem SA, Allsop D et al. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. Biochem. Biophys. Res. Commun.349, 162–166 (2006).
  • El-Agnaf OMA, Salem SA, Paleologou KE et al. Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson’s disease. FASEB J.20, 419–425 (2006).
  • Lee PH, Lee G, Park HJ et al. The plasma α-synuclein levels in patients with Parkinson’s disease and multiple system atrophy. J. Neural Transm.113, 1435–1439 (2006).
  • Li QX, Mok SS, Laughton KM et al. Plasma α-synuclein is decreased in subjects with Parkinson’s disease. Exp. Neurol.204, 583–588 (2007).
  • Mollenhauer B, Cullen V, Kahn I et al. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol.213, 315–325 (2008).
  • Hong Z, Shi M, Chung KA et al. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain133, 713–726 (2010).
  • Shi M, Zabetianb CP, Hancocka AM et al. Significance and confounders of peripheral DJ-1 and α-synuclein in Parkinson’s disease. Neurosci. Lett.480, 78–82 (2010).
  • Anderson JP, Walker DE, Goldstein JM et al. Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem.281, 29739–29752 (2006).
  • Sato H, Arawaka S, Hara S et al. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J. Neurosci.31, 16884–16894 (2011).
  • Foulds PG, Mann DMA, Mitchell JD et al. Progress towards a molecular biomarker for Parkinson disease. Nat. Rev. Neurol.6, 359–361 (2010).
  • Foulds PG, Mitchell JD, Parker A et al. Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson’s disease. FASEB J.25, 4127–4137 (2011).
  • Foulds PG, Yokota O, Thurston A et al. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson’s disease and dementia with Lewy bodies. Neurobiol. Dis.45, 188–195 (2012).
  • Bartels T, Choi JG, Selkoe DJ. α-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature477, 107–110 (2011).
  • Prvulovic D, Hampel H. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer’s disease. Clin. Chem. Lab Med.49, 367–374 (2011).
  • Shaw LM, Vanderstichele H, Knapik-Czajka M et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann. Neurol.65, 403–413 (2009).
  • Fukumoto H, Tokuda T, Kasai T et al. High-molecular weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J.24, 2716–2726 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.